Previous studies have revealed partners of synthetic lethality in ovarian cancer, such as PARP [poly (ADP)-ribose polymerase] against BRCA (breast cancer susceptibility protein)-deficient cells [23] and EZH2 (enhancer of zeste homolog 2) against ARID1A (AT-rich interactive domain-containing protein 1A)-mutated cells [24]. This evidence concerns the gene EZH2 and ovarian carcinoma.